Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery

Journal of Thrombosis and Thrombolysis

Volumn 19, Issue 3, 2005, Pages 197-200

  Kunt, Alper Sami ^a   Darcin, Osman Tansel ^a   Aydin, Salih ^a   Demir, Deniz ^a   Selli, Cuneyt ^a   Andac, Mehmet Halit ^a  

^a HARRAN UNIVERSITY   (Turkey)

Author keywords

Aprotinin; Cardio pulmonary bypass; Coronary artery bypass grafting

Indexed keywords

APROTININ; D DIMER;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD TRANSFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HUMAN; INTRAOPERATIVE PERIOD; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE HEMORRHAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; STUDENT T TEST;

AGED; APROTININ; BLOOD LOSS, SURGICAL; BLOOD TRANSFUSION; CORONARY ARTERY BYPASS; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HUMANS; INTRAOPERATIVE CARE; MALE; MIDDLE AGED;

EID: 23844451705     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-005-1714-x     Document Type: Article

References (8)

1. Linde MD. The hemostatic defect of cardiopulmonary bypass. Journal of Thrombosis and Thrombolysis 2003;16(3):129-147. 10.1023/ B:THRO.0000024051.12177.e9
2. Englberger L, Kipfer B, Berdat PA, Nydegger UE, Carrel TP. Aprotinin in coronary operation with cardiopulmonary bypass: Does "low-dose" aprotinin inhibit the inflammatory response? Ann Thorac Surg 2002;73(6):1897-1904. 10.1016/S0003-4975(02)03535-X
3. Lemmer JH Jr, Dilling EW, Morton Jr, Rich JB, Robicsek F, Bricker DL, et al. Aprotinin for primary coronary artery bypass grafting: A multicenter trial of three dose regimens. Ann Thorac Surg 1996;62(6):1659-1668. 10.1016/S0003-4975(96)00451-1
4. Hayashida N, Isomura T, Sato T, Maruyama H, Kosuga K, Aoyagi S. Effects of minimal-dose aprotinin on coronary artery bypass grafting. J Thorac Cardiovasc Surg 1997;114(2):261-269. 9270645
5. Merritt JC, Bhatt DL. The efficacy and safety of perioperative antiplatelet therapy. Journal of Thrombosis and Thrombolysis 2004;17(1):21-27. 10.1023/B:THRO.0000036025.07348.f1
6. Davis R, Whittington R. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery. Drugs 1995;49(6):954-983. 7543841
7. Speekenbrink RG, Wildevuur CR, Sturk A, Eijsman L. Low-dose and high-dose aprotinin improve hemostasis in coronary operations. J Thorac Cardiovasc Surg 1996;112(2):523-530. 8751522
8. Linde MD. The hemostatic defect of cardiopulmonary bypass. Journal of Thrombosis and Thrombolysis 2003;16(3):129-147. 10.1023/ B:THRO.0000024051.12177.e9